PROBENAZOL


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	WHHIPMZEDGBUCC-UHFFFAOYSA-N
Smiles	C=CCOC1=NS(=O)(=O)c2ccccc12
InChI	InChI=1S/C10H9NO3S/c1-2-7-14-10-8-5-3-4-6-9(8)15(12,13)11-10/h2-6H,1,7H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C10H9NO3S
Molecular Weight	223.25
AlogP	1.88
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	3.0
Polar Surface Area	64.11
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	15.0

Assay Description	Organism	Bioactivity
Induction of systemic acquired resistance against Pyricularia oryzae-induced Oryza sativa (rice) blast disease in 2.1 leaf stage Oryza sativa plants Oryza sativa cv. Nipponbare seedlings pre-treated with soil drench application of compound seven days before fungal inoculation assessed as compound level per pot causing protection against blast lesions disease development measured 7 days post fungal inoculation under green house conditions	Oryza sativa	None
Induction of PBZ1 gene expression in three-leaf stage of Oryza sativa (rice) plant leaf after 5 days by Northern blot analysis	Oryza sativa	None
Induction of disease resistant in three-leaf stage of Oryza sativa (rice) plant against Xanthomonas oryzae pv. oryzae-induced leaf blight at 0.05 to 5 mg/pot after 7 days	Oryza sativa	None

Cross References

Resources	Reference
ChEMBL	CHEMBL2287211
PubChem	91587
SureChEMBL	SCHEMBL23516
ZINC	ZINC02564893

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).